Sirnaomics Receives NCI Grant to Develop siRNA-Based Lung Cancer Rx

The six-month grant began on June 1 and is worth $250,000. The company will use the funds to develop multi-targeted siRNA drugs for non-small cell lung cancer.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.